Asymmetrical lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors - PubMed (original) (raw)
Asymmetrical lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors
Anne Y Lai et al. J Exp Med. 2006.
Abstract
The mechanism of lineage commitment from hematopoietic stem cells (HSCs) is not well understood. Although commitment to either the lymphoid or the myeloid lineage is popularly viewed as the first step of lineage restriction from HSCs, this model of hematopoietic differentiation has recently been challenged. The previous identification of multipotent progenitors (MPPs) that can produce lymphocytes and granulocyte/macrophages (GMs) but lacks erythroid differentiation ability suggests the existence of an alternative HSC differentiation program. Contribution to different hematopoietic lineages by these MPPs under physiological conditions, however, has not been carefully examined. In this study, we performed a refined characterization of MPPs by subfractionating three distinct subsets based on Flt3 and vascular cell adhesion molecule 1 expression. These MPP subsets differ in their ability to give rise to erythroid and GM lineage cells but are equally potent in lymphoid lineage differentiation in vivo. The developmental hierarchy of these MPP subsets demonstrates the sequential loss of erythroid and then GM differentiation potential during early hematopoiesis. Our results suggest that the first step of lineage commitment from HSCs is not simply a selection between the lymphoid and the myeloid lineage.
Figures
Figure 1.
Subfractionation of MPPs by Flt3 and VCAM-1 expression. (A) Flt3 and VCAM-1 expression on HSCs and MPPs by FACS analysis. (B) FACS analysis of Flt3 and VCAM-1 expression levels on MPP subsets after two rounds of sorting. The purity of the sorted populations was >95%.
Figure 2.
MegE differentiation potential is restricted to Flt3loVCAM-1+ MPPs. (A) In vitro MegE and GM differentiation potential of MPP subsets assessed by colony-forming assay on methylcellulose. Data represent the average plating efficiency of triplicate methylcellulose cultures of each MPP population. (B) Comparison of MegE-affiliated GATA1 and EpoR expression levels in HSCs, MPP subsets, CLPs, and MEPs by quantitative PCR analysis. GATA1 and EpoR expression levels in HSCs were arbitrarily defined as unit 1. Data shown represent the mean value from triplicate reactions. (C) In vivo MegE differentiation by Flt3loVCAM-1+ MPPs. Peripheral blood from recipient mice injected with Flt3loVCAM-1+ MPPs was analyzed at 2 wk after injection to detect donor-derived (GFP+) CD41+CD61+ platelets. (D) Comparison of in vivo MegE and GM differentiation potential of MPP subsets. Peripheral blood from recipient mice injected with purified MPP subsets was analyzed at 2 wk after injection to evaluate the donor chimerism (GFP+) of CD41+CD61+ platelets (○) or Mac-1+ GM cells (•). Horizontal bars in the graph denote the average values from three mice analyzed in each group. *, P < 0.05, calculated by the Student's t test compared with percentage of chimerism of Flt3loVCAM-1+ MPPs.
Figure 3.
Lymphoid lineage differentiation potential and lymphoid lineage priming in MPP subsets. (A) All MPP subsets contributed to lymphoid lineage differentiation in vivo. Peripheral blood collected from reconstituted mice was analyzed for donor-derived B220+ B cells and CD3+ T cells at 3–5 wk after injection. FACS plot shown is pregated on GFP+CD45.1− population. Almost all B220+ cells are CD19+IgM+, and most CD3+ cells are TCRβ+ in the peripheral blood (Fig. S2). It should be noted that due to the setting of the FACS machine, the CD3+ population does not clearly appear in the plots. (B) Analysis of lymphoid-specific RAG1 and IL-7Rα expression levels in MPP subsets by quantitative PCR. Data shown represent the mean value from triplicate reactions. RAG1 and IL-7Rα expression levels in CLPs were arbitrarily set at 10,000 and 100, respectively.
Figure 4.
Flt3loVCAM-1+ MPPs, but not Flt3hiVCAM-1+ MPPs, differentiate into CMPs in vivo. (A) Detection of CMPs, GMPs, and MEPs derived from Flt3loVCAM-1+ MPPs and Flt3hiVCAM-1+ MPPs. Equal number of cells from the two MPP populations (CD45.2) were injected into CD45.1+ recipient mice. Bone marrow cells were harvested 6 d after injection for FACS analysis, and the total cell number of donor-derived CMPs, GMPs, and MEPs in recipient mice from two independent experiments is shown. FACS plots of these donor-derived bone marrow populations are shown in Fig. S3. Although the chimerism of donor-derived cells in the bone marrow varied between experiments, the difference in the contribution of CMPs, GMPs, and MEPs from Flt3loVCAM-1+ MPPs and Flt3hiVCAM-1+ MPPs remained consistent. (B) Proposed model of hierarchy in MPP subsets and lymphoid- and myeloid lineage–restricted progenitors during hematopoiesis, based on in vivo differentiation potential of MPPs. Flt3loVCAM-1+ MPPs represent the first branching point during adult hematopoiesis, which diverge into CMPs and Flt3hiVCAM-1+ MPPs. Flt3hiVCAM-1+ MPPs represent the second branching point, diverging to lymphoid lineage and a GM differentiation pathway that is independent of CMPs. Because Flt3hiVCAM-1− MPPs do not contribute to GM lineages significantly in vivo, we consider these MPPs as lymphoid-specified progenitors before lymphoid lineage commitment in CLPs or pro–T cells in the thymus. Dotted lines represent potential migration of bone marrow progenitor candidates to the thymus for T cell development based on evidence by recent studies (reference 25).
Similar articles
- Heterogeneity of Flt3-expressing multipotent progenitors in mouse bone marrow.
Lai AY, Lin SM, Kondo M. Lai AY, et al. J Immunol. 2005 Oct 15;175(8):5016-23. doi: 10.4049/jimmunol.175.8.5016. J Immunol. 2005. PMID: 16210604 - Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment.
Adolfsson J, Månsson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, Bryder D, Yang L, Borge OJ, Thoren LA, Anderson K, Sitnicka E, Sasaki Y, Sigvardsson M, Jacobsen SE. Adolfsson J, et al. Cell. 2005 Apr 22;121(2):295-306. doi: 10.1016/j.cell.2005.02.013. Cell. 2005. PMID: 15851035 - Biological and molecular evidence for existence of lymphoid-primed multipotent progenitors.
Luc S, Buza-Vidas N, Jacobsen SE. Luc S, et al. Ann N Y Acad Sci. 2007 Jun;1106:89-94. doi: 10.1196/annals.1392.023. Epub 2007 Apr 18. Ann N Y Acad Sci. 2007. PMID: 17442777 Review. - Identification of Flt3⁺CD150⁻ myeloid progenitors in adult mouse bone marrow that harbor T lymphoid developmental potential.
Chi AW, Chavez A, Xu L, Weber BN, Shestova O, Schaffer A, Wertheim G, Pear WS, Izon D, Bhandoola A. Chi AW, et al. Blood. 2011 Sep 8;118(10):2723-32. doi: 10.1182/blood-2010-09-309989. Epub 2011 Jul 26. Blood. 2011. PMID: 21791413 Free PMC article. - Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors.
Kondo M. Kondo M. Immunol Rev. 2010 Nov;238(1):37-46. doi: 10.1111/j.1600-065X.2010.00963.x. Immunol Rev. 2010. PMID: 20969583 Free PMC article. Review.
Cited by
- Inflammation in Development and Aging: Insights from the Zebrafish Model.
Mastrogiovanni M, Martínez-Navarro FJ, Bowman TV, Cayuela ML. Mastrogiovanni M, et al. Int J Mol Sci. 2024 Feb 10;25(4):2145. doi: 10.3390/ijms25042145. Int J Mol Sci. 2024. PMID: 38396822 Free PMC article. Review. - Deciphering driver regulators of cell fate decisions from single-cell transcriptomics data with CEFCON.
Wang P, Wen X, Li H, Lang P, Li S, Lei Y, Shu H, Gao L, Zhao D, Zeng J. Wang P, et al. Nat Commun. 2023 Dec 20;14(1):8459. doi: 10.1038/s41467-023-44103-3. Nat Commun. 2023. PMID: 38123534 Free PMC article. - An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer.
Martinez-Castillo M, M Elsayed A, López-Berestein G, Amero P, Rodríguez-Aguayo C. Martinez-Castillo M, et al. Noncoding RNA. 2023 Nov 11;9(6):70. doi: 10.3390/ncrna9060070. Noncoding RNA. 2023. PMID: 37987366 Free PMC article. Review. - Flt3 Signaling in B Lymphocyte Development and Humoral Immunity.
Medina KL. Medina KL. Int J Mol Sci. 2022 Jun 30;23(13):7289. doi: 10.3390/ijms23137289. Int J Mol Sci. 2022. PMID: 35806293 Free PMC article. Review. - ILC Differentiation in the Thymus.
Sun XH, Bajana S. Sun XH, et al. Adv Exp Med Biol. 2022;1365:25-39. doi: 10.1007/978-981-16-8387-9_3. Adv Exp Med Biol. 2022. PMID: 35567739
References
- Weissman, I.L. 2000. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science. 287:1442–1446. - PubMed
- Weissman, I.L., D.J. Anderson, and F. Gage. 2001. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu. Rev. Cell Dev. Biol. 17:387–403. - PubMed
- Orkin, S.H. 2000. Diversification of haematopoietic stem cells to specific lineages. Nat. Rev. Genet. 1:57–64. - PubMed
- Zhu, J., and S.G. Emerson. 2002. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene. 21:3295–3313. - PubMed
- Laiosa, C.V., M. Stadtfeld, and T. Graf. 2006. Determinants of lymphoid-myeloid lineage diversification. Annu. Rev. Immunol. 24:705–738. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AI056123/AI/NIAID NIH HHS/United States
- AI52077/AI/NIAID NIH HHS/United States
- AI056123/AI/NIAID NIH HHS/United States
- T32 AI052077/AI/NIAID NIH HHS/United States
- CA098129/CA/NCI NIH HHS/United States
- R01 CA098129/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous